Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis

INTRODUCTION: The use of immune checkpoint inhibitors (ICIs) as a front-line treatment for metastatic renal cell carcinoma (RCC) has significantly improved patient’ outcome. However, little is known about the efficacy or lack thereof of immunotherapy after prior use of anti-PD1/PD-L1 or/and anti-CTL...

Descripción completa

Detalles Bibliográficos
Autores principales: Papathanassiou, Maria, Tamposis, Ioannis, Exarchou-Kouveli, Kalliopi K., Kontou, Panagiota I., de Paz, Anna Tzortzi, Mitrakas, Lampros, Samara, Maria, Bagos, Pantelis G., Tzortzis, Vassilios, Vlachostergios, Panagiotis J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756433/
https://www.ncbi.nlm.nih.gov/pubmed/36531034
http://dx.doi.org/10.3389/fonc.2022.996553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756433/
https://www.ncbi.nlm.nih.gov/pubmed/36531034
http://dx.doi.org/10.3389/fonc.2022.996553

Ejemplares similares